PEGMOLESATIDE RECOMMENDED IN EXPERT CONSENSUS AS LONG-ACTING AGENT IN THE TREATMENT OF RENAL ANEMIA
Recently, the Chinese Journal of Nephrologyreleased the “Chinese Expert Consensus on Long-Acting Erythropoiesis-Stimulating Agents in the Treatment of Renal Anemia (2024)”[1](the “Consensus”), in whichHansoh Pharma’s pegmolesatide (trade name: Saint Luolai )was recommended in the Consensus for the first time.
According to the Consensus, long-acting agents in the treatment of renal anemia are commonly used in international markets, such as America, European countries and Japan, yet short-acting rHuEPOs are still a mainstay in China. Compared with short-acting rHuEPOs, long-acting agents that can effectively reduce the frequency of injections, relieve the workload of healthcare professionals, and enhance patient compliance, have become a significant direction in improving the treatment of renal anemia.
This Consensus recommends the clinical use of long-acting ESAs for the treatment of renal anemia in non-dialysis and dialysis-dependent CKD patients (with 1A evidence). This will further promote the clinical application of long-acting ESAs and improve the standard of renal anemia management in China.
The Consensus also suggests that attention be paid to safety monitoring during treatment with long-acting drugs, and it also points out that pegmolesatide does not have immune cross-reactivity with endogenous EPO due to lack of homology in the amino acid sequence of endogenous EPO, thus enabling greater protection against anti-EPO antibody-mediated pure red cell anemia (PRCA).
Independently developed by Hansoh Pharma, pegmolesatide is the only marketed EPO mimetic peptide worldwide. It was approved by the NMPA in June 2023, and included in the 2023 National Reimbursement Drug List (NRDL), opening a new chapter in the long-term effective management of renal anemia in Chinese patients with CKD. Unlike other long-acting drugs, the phase III clinical trial data on pegmolesatides is based on Chinese populations and has shown definite efficacy in both dialysis patients and non-dialysis CKD patients with anemia, thus providing better guidance for medication in Chinese patients with renal anemia.
In October 2023, eClinicalMedicine(IF:15.1), the electronic journal from the world's top medical journalThe Lancet, released a paper on the phase III clinical trial of pegmolesatide. The results of this randomized, open-label, active-comparator, non-inferiority phase III study on anemic patients undergoing dialysis and short-acting rHuEPO treatment showed that monthly subcutaneous injection of pegmolesatide was as effective and safe as conventional short-acting rHuEPO administrated one to three times a week. Despite the fact that it is a non-inferiority study, inferiority for pegmolesatide was established in the primary efficacy endpoint (between-group variance 0.29g/dL, 95% CI: 0.11～0.47, p=0.0018)[2].
As China's independently-developed Class 1 innovative drug, pegmolesatide was included in the NRDL, and recommended by the Concensus as soon as it hit the market, benefiting renal anemia patients with its clinical accessibility and affordability. Hansoh Pharma will continue to focus on areas where the company boasts advantages, tap into unmet clinical needs, and launch more breakthrough innovative drugs to improve the quality of human life.
References:
[1] Expert Committee of Nephrology & Dialysis Branch of China Non-Government Medical Institutions Association. Chinese Expert Consensus on Long-Acting Erythropoiesis-Stimulating Agents in the Treatment of Renal Anemia (2024) [J]Chinese Journal of Nephrology,2024,40(2):146-157.
[2] Ping Zhang, et al. Pegmolesatide for the treatment of anemia in patients undergoing dialysis: a randomized clinical trial.eClinicalMedicine. 2023 Oct 28; 65:102273
Note: this article is intended as a reference material for healthcare professionals, and shall not be used as a basis for treatment or recommendations.
Hansoh Pharma is a leading innovation-driven pharmaceutical enterprise headquartered in China. With the mission of "continuous innovation for better life", the company focuses on major disease therapeutic areas such as oncology, anti-infectives, central nervous system (CNS), metabolism and immunology. Hansoh Pharma has launched 7 innovative drugs that generate product sales in China, with the revenue from innovative drugs and collaborative products exceeding 80%, forming a rich product pipeline. The company has consistently ranked among the top 100 global pharmaceutical companies and is recognized as one of the top 3 pharmaceutical R&D enterprises in China and is designated as a National Key High-Tech Enterprise and a National Technology Innovation Demonstration Enterprise. Hansoh Pharma was listed on the Hong Kong Stock Exchange in June 2019 (stock code: 03692.HK).
1. This announcement is intended for healthcare professionals only and not for advertising purposes.2. Hansoh Pharma does not recommend the use of any unapproved drugs or off-label indications, nor does it make recommendations regarding any drug or indication.3. The information provided in this announcement is for reference only; please follow the advice or guidance of a physician or other healthcare professional. Any treatment-related decisions made by healthcare professionals should be based on the specific circumstances of the patient and should be used in accordance with the instructions for the drug.4. For more detailed information about any company products, medical treatments, or diseases, please consult a healthcare professional.
Forward-Looking Statements
This press release is intended to provide information about Hansoh Pharmaceutical Group Co., Ltd. and its affiliates, including their subsidiaries (collectively referred to as "Hansoh Pharma"). It does not constitute a disclosure of information about Hansoh Pharma or any investment recommendations.The information contained in this release may include forward-looking statements related to Hansoh Pharma's business and product prospects, as well as its plans, beliefs, expectations, and strategies. These statements are predictions based on speculative assumptions and are not guarantees of future performance. They are subject to risks and uncertainties, such as scientific, commercial, political, economic, financial, legal factors as well as competitive environment and social conditions, many of which are beyond Hansoh Pharma's control and difficult to predict, thus actual results may differ significantly from what is stated here, and past securities price trends should not be used as a guide for future market conditions. As such, investors should exercise caution when using this information to make investment decisions. Phrases such as "commit," "expect," "believe," "predict," "anticipate," "forecast," "intent,"“project,” “may,” “will,” “should,” “plan,” “could,” “continue,” “target,” “contemplate,” “estimate,” “guidance,” “possible,” “potential,” “pursue,”“likely,”and words and terms of similar terms substance used in connection with any discussion of future plans, actions or events indicate forward-looking statements.Hansoh Pharma does not commit to or guarantee the accuracy, timeliness, or completeness of forward-looking information and assumes no obligation to update or revise these forward-looking statements. Neither Hansoh Pharma nor any of its directors, employees, or agents will be responsible for any forward-looking statements that prove to be inaccurate or unachievable and any losses or damages incurred by users due to reliance on the information provided herein, including but not limited to direct, incidental, indirect, or punitive damages.All information in this press release is current as of the date of release. Hansoh Pharma assumes no responsibility to update or revise this information in light of new developments, future events, or other circumstances, except as required by law. Additionally, Hansoh Pharma reserves the right to make changes, corrections, or discontinuations to all or part of the content of this press release at any time without notice. For information specifically related to the listed company, investors are encouraged to refer to the announcements and financial reports of Hansoh Pharma (03692.HK).
